XML 67 R54.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaborative Agreements (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Dec. 31, 2017 | Dec. 29, 2017 | Jun. 30, 2020 | Apr. 30, 2020 | Mar. 31, 2020 | Jan. 31, 2020 | Aug. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Oct. 31, 2018 | Apr. 30, 2018 | Mar. 31, 2018 | Sep. 30, 2015 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Jun. 30, 2018 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 272,824 |  | $ 267,187 |  | $ 643,945 | $ 1,594,461 |
Grant funding liability |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,859,155 |  |  |  | 6,859,155 |  | $ 7,474,310
Advaccine | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 0 |  | 7,100,000
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | 82,923 |  | 74,102 |  | 122,538 | 145,602 |
Advaccine | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000.0 |  |
Additional revenue to be achieved |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 206,000,000.0 |  |
Collaboration Agreement, Payment Earned |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000.0 |  |
Royalty period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |
Annual maintenance fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |
Annual maintenance period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  | $ 0 |  |
ApolloBio | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  | $ 23,000,000.0 |  |  |  |  | $ 23,000,000.0 | 23,000,000.0 |  |
Additional revenue to be achieved |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |
Royalty period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |
Period from effective date for termination |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |
Territory expansion option period |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds received in upfront payment |  |  |  |  |  |  |  |  |  |  |  | 19,400,000 |  |  |  |  |  |  |  |
Advisory fees |  |  |  |  |  |  |  |  |  |  |  | 960,000 |  |  |  |  |  |  |  |
Number of days written notice before termination |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign corporate income taxes reducing upfront payment |  |  |  |  |  |  |  |  |  |  |  | 2,200,000 |  |  |  |  |  |  |  |
Foreign non-corporate income taxes reducing upfront payment |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |  |  |  |  |  |
AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  | $ 2,000,000.0 | $ 2,000,000.0 |  |  |  |  |  |  |  |  |  |  |
AstraZeneca | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 27,500,000 |  |  |  |  |  |  |  |  |  |  |  | $ 27,500,000 |  |  |  |  |  |  |
Anticipated development and regulatory event based payment receivable milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000,000 |  |
Anticipated commercial event based payment receivable milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115,000,000 |  |
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received |  |  |  | $ 6,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received |  |  |  |  |  |  |  |  |  |  | $ 56,000,000 |  |  |  |  |  |  |  |  |
Collaborative agreement, period to receive funding for research and development |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,100,000 |  | 1,800,000 |  | 4,400,000 | 2,900,000 |
Grant funding liability |  |  |  |  |  |  |  |  |  |  |  |  |  | 316,000 |  |  |  | 316,000 |  |
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received |  |  |  |  |  | $ 9,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,100,000 |  | 5,800,000 |  | 3,500,000 | 8,100,000 |
Grant funding liability |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,900,000 |  |  |  | 2,900,000 |  |
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received |  |  |  | 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received |  |  |  | $ 1,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  | 0 |  | 850,000 |  | 893,000 | 913,000 |
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  |  |  |  |  | $ 1,100,000 |  |  | $ 2,200,000 |  |  |  |  |  | 36,000 |  |  | 170,000 |
Grant funding liability |  |  |  |  |  |  |  |  |  |  |  |  |  | 575,000 |  |  |  | 575,000 |  |
Department of Defence | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contra-research and development expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,400,000 |  | $ 0 |  | 21,200,000 | $ 0 |
Accounts receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,900,000 |  |  |  | 12,900,000 |  | $ 11,400,000
Deferred grant funding, from affiliate |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  | $ 3,000,000.0 |  |
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  | $ 54,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price, procurement contract |  |  | $ 16,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Annual Maintenance Period + References No definition available. + Details
Name: | ino_AnnualMaintenancePeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Additional Revenue To Be Achieved + References No definition available. + Details
Name: | ino_CollaborationAgreementAdditionalRevenueToBeAchieved
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones + References No definition available. + Details
Name: | ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones + References No definition available. + Details
Name: | ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Payment Earned + References No definition available. + Details
Name: | ino_CollaborationAgreementPaymentEarned
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Royalty Period + References No definition available. + Details
Name: | ino_CollaborationAgreementRoyaltyPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Territory Expansion Option Period + References No definition available. + Details
Name: | ino_CollaborationAgreementTerritoryExpansionOptionPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Advisory Fees + References No definition available. + Details
Name: | ino_CollaborativeAgreementAdvisoryFees
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Agreement, Corporate Income Tax + References No definition available. + Details
Name: | ino_CollaborativeAgreementCorporateIncomeTax
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Non-Income Taxes + References No definition available. + Details
Name: | ino_CollaborativeAgreementForeignNonIncomeTaxes
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Funding Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementFundingReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Funding Received for Research and Development + References No definition available. + Details
Name: | ino_CollaborativeAgreementFundingToBeReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Number of Days Written Notice Before Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Period From Effective Date For Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Period to Receive Funding for Research and Development + References No definition available. + Details
Name: | ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreements, Upfront Payment Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementsUpfrontPaymentReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Fixed-Price Contract, Amount Awarded + References No definition available. + Details
Name: | ino_CollaborativeArrangementFixedPriceContractAmountAwarded
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Deferred Grant Funding, Current + References No definition available. + Details
Name: | ino_DeferredGrantFundingCurrent
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Grant Proceeds Received + References No definition available. + Details
Name: | ino_GrantProceedsReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds From Collaborative Agreement + References No definition available. + Details
Name: | ino_ProceedsFromCollaborativeAgreement
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 310 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an unclassified balance sheet, amount of receivables arising from transactions with related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsReceivableRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=ino_AdvaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_AdvaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_ApolloBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_INO4800Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |